FP04.03 Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1
暂无分享，去创建一个
N. Rizvi | I. Lowy | I. Bondarenko | M. Gumus | V. Sriuranpong | P. Clingan | G. Gullo | H. Turk | A. Sezer | I. Çiçin | O. Gladkov | F. Seebach | S. Kılıçkap | J. Pouliot | M. Ozguroglu | P. Rietschel | D. Bentsion | S. Lee | J. Mcginniss | M. Gogishvili